We are live on ! Find out more
IRD

Opus Genetics
IRD

31 hedge funds and large institutions have $5.71M invested in Opus Genetics in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

11% less funds holding

Funds holding: 35 → 31 (-4)

13% less capital invested

Capital invested by funds: $6.57M → $5.71M (-$853K)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

Holders
31
Holders Change
-4
Holders Change %
-11.43%
% of All Funds
0.9%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
8
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$399K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$151K
3
Goldman Sachs
Goldman Sachs
New York
+$72.4K
4
CCM
Condor Capital Management
New Jersey
+$47.5K
5
VKH
Virtu KCG Holdings
New York
+$45K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.07M
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$63K
3
GC
Guggenheim Capital
Illinois
-$34.9K
4
Citadel Advisors
Citadel Advisors
Florida
-$32.1K
5
OC
Oppenheimer & Co
New York
-$23K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.33M +$399K +1,108 +15%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$742K +$151K +420 +28%
Northern Trust
3
Northern Trust
Illinois
$190K -$360 -1 -0.2%
AQR Capital Management
4
AQR Capital Management
Connecticut
$173K – – –
BCM
5
Bridgeway Capital Management
Texas
$146K – – –
CCM
6
Condor Capital Management
New Jersey
$145K +$47.5K +132 +55%
Wells Fargo
7
Wells Fargo
California
$134K +$9.36K +26 +8%
Goldman Sachs
8
Goldman Sachs
New York
$128K +$72.4K +201 +157%
NFC
9
Northeast Financial Consultants
Connecticut
$121K – – –
Bank of New York Mellon
10
Bank of New York Mellon
New York
$104K – – –
Deutsche Bank
11
Deutsche Bank
Germany
$85K +$2.16K +6 +3%
BMC
12
Benin Management Corp
Connecticut
$67K – – –
VKH
13
Virtu KCG Holdings
New York
$66K +$45K +125 +278%
Bank of America
14
Bank of America
North Carolina
$65K +$11.5K +32 +24%
BA
15
BlackRock Advisors
Delaware
$29K – – –
State Street
16
State Street
Massachusetts
$29K – – –
Citadel Advisors
17
Citadel Advisors
Florida
$26K -$32.1K -89 -57%
Commonwealth Equity Services
18
Commonwealth Equity Services
Massachusetts
$19K -$63K -175 -78%
MC
19
Moors & Cabot
Massachusetts
$19K – – –
ASN
20
Advisory Services Network
Georgia
$18K – – –
GC
21
Guggenheim Capital
Illinois
$16K -$34.9K -97 -70%
Creative Planning
22
Creative Planning
Kansas
$16K +$15.1K +42 New
LTFS
23
Ladenburg Thalmann Financial Services
Florida
$14K – – –
FA
24
FCG Advisors
New Jersey
$12K +$11.2K +31 New
FHC
25
First Heartland Consultants
Missouri
$8K +$7.56K +21 New
1
2

IRD Hedge Fund Activity: Q3 2014 in Review

31 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2014, worth a combined $5.71M — down 13% from $6.57M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of IRD and 3 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 8 added.

The largest buyer was Vanguard Group, adding an estimated $399K. The largest seller was Morgan Stanley, exiting entirely with an estimated $1.07M sold.

  • 31 institutional investors held Opus Genetics (IRD) as of Q3 2014, down from 35 in Q2 2014.
  • Funds reported $5.71M of Opus Genetics stock for Q3 2014, down 13% quarter-over-quarter.
  • 3 funds opened new Opus Genetics positions in Q3 2014 and 7 closed out, a net change of -4 holders.
  • The largest Opus Genetics buyer in Q3 2014 was Vanguard Group, an estimated $399K added.
  • The largest Opus Genetics seller in Q3 2014 was Morgan Stanley, an estimated $1.07M sold.

Based on aggregated 13F filings for Q3 2014.